cbsnews.com/news/obesity-r…

LillyDirect and Walmart Pharmacy Launch First Retail Pick-Up Option With Direct-to-Consumer Pricing for Zepbound corporate.walmart.com/news/2025/10/2…

Dual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease Study medpagetoday.com/meetingcoverag…

We've just launched the first large, site-less (home, direct to participant) randomized trial for treatment of #LongCovid, testing tirzepatide (a GLP-1 drug) vs placebo. Please help spread the word scripps.edu/news-and-event…

Eli Lilly, Novo Nordisk negotiating deal with Trump administration on obesity drug prices - ABC News via ABC News - abcnews.go.com/Health/eli-lil…

Exciting updates today in the world of obesity medicine!

JCI - Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits jci.org/articles/view/…

Surprising heart study finds daily coffee may cut AFib risk by 39% sciencedaily.com/releases/2025/…

GLP-1 medications tied to dramatically lower cancer deaths sciencedaily.com/releases/2025/…

Eli Lilly cuts price for popular weight-loss drug Zepbound usatoday.com/story/money/20… via USA TODAY

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial investor.lilly.com/news-releases/…

⁦Eli Lilly and Company⁩ ‘s orforglipron helped people maintain #weightloss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial HT ⁦On The Pen™⁩ prnewswire.com/news-releases/…

Yet another study showing similar muscle growth when using heavy vs light loads. The evidence is overwhelming on the topic: loading ranges of ~5 to 30 reps build muscle equally. Very nice study design from the lab of Stuart Phillips (he/him) 💪 physoc.onlinelibrary.wiley.com/doi/10.1113/JP…

2026 will bring waves of innovation to GLP-1 medicines from mechanisms to modalities to molecules delivery systems and new indications. #weightloss #obesity A glimpse of the.future here nature.com/articles/s4159…

Increasing reliance on #CashPay healthcare leaves many working class people out in the cold. Increasingly, money talks in healthcare and everyone else walks – if they don’t have the cash to pay for healthcare. Especially for obesity care. HT: Joe Zucchi, PA-C, CPT conscienhealth.org/2026/02/03/cas…

Intermittent fasting no better than typical weight loss diets, study finds theguardian.com/science/2026/f…

Stopping GLP-1 drugs can quickly erase cardiovascular benefits medicine.washu.edu/news/stopping-… via WashU Medicine

Study Links Higher Vitamin D Levels to Lower Dementia Risk via Everyday Health everydayhealth.com/neurological-d…

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions investor.lilly.com/news-releases/…